Clinical Trials Logo

Metastatic Anal Canal Carcinoma clinical trials

View clinical trials related to Metastatic Anal Canal Carcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02560298 Active, not recruiting - Clinical trials for Anal Squamous Cell Carcinoma

Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer

InterAACT
Start date: August 23, 2016
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well cisplatin and fluorouracil work compared with carboplatin and paclitaxel in treating patients with anal cancer that cannot be removed by surgery, has come back at or near the same place as the primary tumor, or spread to other places in the body. Drugs used in chemotherapy, such as cisplatin, fluorouracil, carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin and fluorouracil are more effective than carboplatin and paclitaxel in treating anal cancer.

NCT ID: NCT02314169 Active, not recruiting - Clinical trials for Anal Canal Squamous Cell Carcinoma

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

Start date: May 13, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with anal canal cancer that has not responded to previous treatment (refractory) and that has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.